Succinic acid
|
Basic information |
| Metabolite name | Succinic acid |
 | HMDB0000254 |
 |
C00042 |
 |
1110 |
| Synonyms | butanedioic acid; |
| No. of studies | 68 |
|
Basic information |
| Metabolite name | Succinic acid |
| HMDB0000254 |
|
C00042 |
|
1110 |
| Synonyms | butanedioic acid; |
| No. of studies | 68 |
|
Relationship between Succinic acid and depression (count: 68) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M055 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M055 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M055 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M060 | Type1 | test set: depressed group vs. control group | Peripheral blood mononuclear cell | Human | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M078 | Type1 | CORT model group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Down |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Urine | Cynomolgus monkey | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Faece | CD-1 mouse | Down |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1061 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M1074 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type3 | venlafaxine group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Up |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M615 | Type1 | high-fat diet group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M664 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M664 | Type2 | CSDS + Dl-3-n-butylphthalide group vs. CSDS group | Hippocampus | C57BL/6 J mouse | Down |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Down |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Up |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M787 | Type1 | CRS group vs. control group | Colon | Wistar rat | Up |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M826 | Type1 | CVS group vs. control group | Ileum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Colorectum | Wistar rat | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M843 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M849 | Type1 | CUMS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M863 | Type1 | CSDS group vs. control group | Medial prefrontal cortex | C57BL/6J mouse | Down |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M975 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M975 | Type2 | CUMS + middle dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + high dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M975 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Up |